| 1 | transplant | 5,940 |
| 2 | injury/acute | 28 |
| 3 | disease-mineral | 11 |
| 4 | heart-transplant | 11 |
| 5 | kidney-transplant | 10 |
| 6 | cmv-seronegative | 9 |
| 7 | foundation-kidney | 8 |
| 8 | lung-transplant | 8 |
| 9 | renal-transplant | 8 |
| 10 | disease-epidemiology | 6 |
| 11 | failure.the | 6 |
| 12 | hypertrophy/heart | 6 |
| 13 | oxygenation-treated | 6 |
| 14 | d+r- | 4 |
| 15 | text-plus-pictogram | 4 |
| 16 | a-aldlt | 3 |
| 17 | cmv-negative | 3 |
| 18 | cytomegalovirus-negative | 3 |
| 19 | daclizumab-treated | 3 |
| 20 | diseases.the | 3 |
| 21 | function-dependent | 3 |
| 22 | macrolide-susceptible | 3 |
| 23 | 3802 | 2 |
| 24 | atg-treated | 2 |
| 25 | cancer-13 | 2 |
| 26 | cancer/other | 2 |
| 27 | essence-replenishing | 2 |
| 28 | function.the | 2 |
| 29 | heart-lung-transplant | 2 |
| 30 | injury/ards | 2 |
| 31 | ischemia-reperfusion-induced | 2 |
| 32 | oedema-like | 2 |
| 33 | oestrous-synchronised | 2 |
| 34 | paranchymal | 2 |
| 35 | 151/living | 1 |
| 36 | 17,468 | 1 |
| 37 | 33.23 | 1 |
| 38 | 4.bone | 1 |
| 39 | 6,607 | 1 |
| 40 | agenesia | 1 |
| 41 | anomalies-a | 1 |
| 42 | aulacomya | 1 |
| 43 | bms-only | 1 |
| 44 | cancer.an | 1 |
| 45 | cases/76,000 | 1 |
| 46 | cell-vaccinated | 1 |
| 47 | cells/lymphoid | 1 |
| 48 | cells/madin-darby | 1 |
| 49 | cl24/28 | 1 |
| 50 | cmv-naïve | 1 |
| 51 | cmv-sero-negative | 1 |
| 52 | cmv-sero-positive | 1 |
| 53 | concentrate/transfused | 1 |
| 54 | crossmatch-positive | 1 |
| 55 | ctc-derived | 1 |
| 56 | cytomegalovirus-positive | 1 |
| 57 | d4t/ddi | 1 |
| 58 | damage-was | 1 |
| 59 | db-placebo | 1 |
| 60 | defect/systemic | 1 |
| 61 | dehydropeptidase | 1 |
| 62 | disease-tno/azl | 1 |
| 63 | disease.110 | 1 |
| 64 | disease.within-trial | 1 |
| 65 | disease/end-stage | 1 |
| 66 | disease/international | 1 |
| 67 | disease/urinary | 1 |
| 68 | diseases-sponsored | 1 |
| 69 | dms-273 | 1 |
| 70 | eight/100 | 1 |
| 71 | ex-db-ir | 1 |
| 72 | ex-placebo | 1 |
| 73 | failure-induced | 1 |
| 74 | failure-specific | 1 |
| 75 | fibrosis/cirrhosis-induced | 1 |
| 76 | function/patient-reported | 1 |
| 77 | growth-for | 1 |
| 78 | growth.the | 1 |
| 79 | hdv-negative | 1 |
| 80 | id-primed | 1 |
| 81 | impairment/renal | 1 |
| 82 | infarcts.the | 1 |
| 83 | injury-acute | 1 |
| 84 | ir+ | 1 |
| 85 | itx | 1 |
| 86 | kidney-graft | 1 |
| 87 | lc-12 | 1 |
| 88 | pimelosis | 1 |
| 89 | rha+gla/se | 1 |
| 90 | saiwai | 1 |
| 91 | solid-organ-transplant | 1 |
| 92 | system/cell | 1 |
| 93 | transfusions/100 | 1 |
| 94 | transplant-not | 1 |
| 95 | transplantation.this | 1 |
| 1 | 151/living | 1 |
| 2 | 17,468 | 1 |
| 3 | 33.23 | 1 |
| 4 | 3802 | 2 |
| 5 | 4.bone | 1 |
| 6 | 6,607 | 1 |
| 7 | a-aldlt | 3 |
| 8 | agenesia | 1 |
| 9 | anomalies-a | 1 |
| 10 | atg-treated | 2 |
| 11 | aulacomya | 1 |
| 12 | bms-only | 1 |
| 13 | cancer-13 | 2 |
| 14 | cancer.an | 1 |
| 15 | cancer/other | 2 |
| 16 | cases/76,000 | 1 |
| 17 | cell-vaccinated | 1 |
| 18 | cells/lymphoid | 1 |
| 19 | cells/madin-darby | 1 |
| 20 | cl24/28 | 1 |
| 21 | cmv-naïve | 1 |
| 22 | cmv-negative | 3 |
| 23 | cmv-sero-negative | 1 |
| 24 | cmv-sero-positive | 1 |
| 25 | cmv-seronegative | 9 |
| 26 | concentrate/transfused | 1 |
| 27 | crossmatch-positive | 1 |
| 28 | ctc-derived | 1 |
| 29 | cytomegalovirus-negative | 3 |
| 30 | cytomegalovirus-positive | 1 |
| 31 | d+r- | 4 |
| 32 | d4t/ddi | 1 |
| 33 | daclizumab-treated | 3 |
| 34 | damage-was | 1 |
| 35 | db-placebo | 1 |
| 36 | defect/systemic | 1 |
| 37 | dehydropeptidase | 1 |
| 38 | disease-epidemiology | 6 |
| 39 | disease-mineral | 11 |
| 40 | disease-tno/azl | 1 |
| 41 | disease.110 | 1 |
| 42 | disease.within-trial | 1 |
| 43 | disease/end-stage | 1 |
| 44 | disease/international | 1 |
| 45 | disease/urinary | 1 |
| 46 | diseases-sponsored | 1 |
| 47 | diseases.the | 3 |
| 48 | dms-273 | 1 |
| 49 | eight/100 | 1 |
| 50 | essence-replenishing | 2 |
| 51 | ex-db-ir | 1 |
| 52 | ex-placebo | 1 |
| 53 | failure-induced | 1 |
| 54 | failure-specific | 1 |
| 55 | failure.the | 6 |
| 56 | fibrosis/cirrhosis-induced | 1 |
| 57 | foundation-kidney | 8 |
| 58 | function-dependent | 3 |
| 59 | function.the | 2 |
| 60 | function/patient-reported | 1 |
| 61 | growth-for | 1 |
| 62 | growth.the | 1 |
| 63 | hdv-negative | 1 |
| 64 | heart-lung-transplant | 2 |
| 65 | heart-transplant | 11 |
| 66 | hypertrophy/heart | 6 |
| 67 | id-primed | 1 |
| 68 | impairment/renal | 1 |
| 69 | infarcts.the | 1 |
| 70 | injury-acute | 1 |
| 71 | injury/acute | 28 |
| 72 | injury/ards | 2 |
| 73 | ir+ | 1 |
| 74 | ischemia-reperfusion-induced | 2 |
| 75 | itx | 1 |
| 76 | kidney-graft | 1 |
| 77 | kidney-transplant | 10 |
| 78 | lc-12 | 1 |
| 79 | lung-transplant | 8 |
| 80 | macrolide-susceptible | 3 |
| 81 | oedema-like | 2 |
| 82 | oestrous-synchronised | 2 |
| 83 | oxygenation-treated | 6 |
| 84 | paranchymal | 2 |
| 85 | pimelosis | 1 |
| 86 | renal-transplant | 8 |
| 87 | rha+gla/se | 1 |
| 88 | saiwai | 1 |
| 89 | solid-organ-transplant | 1 |
| 90 | system/cell | 1 |
| 91 | text-plus-pictogram | 4 |
| 92 | transfusions/100 | 1 |
| 93 | transplant | 5,940 |
| 94 | transplant-not | 1 |
| 95 | transplantation.this | 1 |
| 1 | ir+ | 1 |
| 2 | d+r- | 4 |
| 3 | cases/76,000 | 1 |
| 4 | transfusions/100 | 1 |
| 5 | eight/100 | 1 |
| 6 | disease.110 | 1 |
| 7 | 3802 | 2 |
| 8 | lc-12 | 1 |
| 9 | cancer-13 | 2 |
| 10 | 33.23 | 1 |
| 11 | dms-273 | 1 |
| 12 | 6,607 | 1 |
| 13 | cl24/28 | 1 |
| 14 | 17,468 | 1 |
| 15 | anomalies-a | 1 |
| 16 | agenesia | 1 |
| 17 | aulacomya | 1 |
| 18 | failure-specific | 1 |
| 19 | defect/systemic | 1 |
| 20 | failure-induced | 1 |
| 21 | ischemia-reperfusion-induced | 2 |
| 22 | fibrosis/cirrhosis-induced | 1 |
| 23 | id-primed | 1 |
| 24 | diseases-sponsored | 1 |
| 25 | oestrous-synchronised | 2 |
| 26 | concentrate/transfused | 1 |
| 27 | daclizumab-treated | 3 |
| 28 | atg-treated | 2 |
| 29 | oxygenation-treated | 6 |
| 30 | cell-vaccinated | 1 |
| 31 | function/patient-reported | 1 |
| 32 | ctc-derived | 1 |
| 33 | cells/lymphoid | 1 |
| 34 | disease/end-stage | 1 |
| 35 | failure.the | 6 |
| 36 | growth.the | 1 |
| 37 | function.the | 2 |
| 38 | diseases.the | 3 |
| 39 | infarcts.the | 1 |
| 40 | oedema-like | 2 |
| 41 | macrolide-susceptible | 3 |
| 42 | 4.bone | 1 |
| 43 | rha+gla/se | 1 |
| 44 | dehydropeptidase | 1 |
| 45 | injury-acute | 1 |
| 46 | injury/acute | 28 |
| 47 | cmv-sero-negative | 1 |
| 48 | cytomegalovirus-negative | 3 |
| 49 | hdv-negative | 1 |
| 50 | cmv-negative | 3 |
| 51 | cmv-seronegative | 9 |
| 52 | crossmatch-positive | 1 |
| 53 | cmv-sero-positive | 1 |
| 54 | cytomegalovirus-positive | 1 |
| 55 | cmv-naïve | 1 |
| 56 | essence-replenishing | 2 |
| 57 | 151/living | 1 |
| 58 | saiwai | 1 |
| 59 | d4t/ddi | 1 |
| 60 | disease.within-trial | 1 |
| 61 | paranchymal | 2 |
| 62 | impairment/renal | 1 |
| 63 | disease/international | 1 |
| 64 | disease-mineral | 11 |
| 65 | system/cell | 1 |
| 66 | disease-tno/azl | 1 |
| 67 | text-plus-pictogram | 4 |
| 68 | cancer.an | 1 |
| 69 | db-placebo | 1 |
| 70 | ex-placebo | 1 |
| 71 | cancer/other | 2 |
| 72 | ex-db-ir | 1 |
| 73 | growth-for | 1 |
| 74 | damage-was | 1 |
| 75 | injury/ards | 2 |
| 76 | transplantation.this | 1 |
| 77 | pimelosis | 1 |
| 78 | kidney-graft | 1 |
| 79 | a-aldlt | 3 |
| 80 | transplant | 5,940 |
| 81 | lung-transplant | 8 |
| 82 | heart-lung-transplant | 2 |
| 83 | renal-transplant | 8 |
| 84 | solid-organ-transplant | 1 |
| 85 | heart-transplant | 11 |
| 86 | kidney-transplant | 10 |
| 87 | function-dependent | 3 |
| 88 | transplant-not | 1 |
| 89 | hypertrophy/heart | 6 |
| 90 | itx | 1 |
| 91 | cells/madin-darby | 1 |
| 92 | foundation-kidney | 8 |
| 93 | disease-epidemiology | 6 |
| 94 | bms-only | 1 |
| 95 | disease/urinary | 1 |